[ASC-J9 for castration-resistant prostate cancer]

Shinichi Yamashita, Yoichi Arai

Research output: Contribution to journalArticlepeer-review


Androgen deprivation therapy has been the standard treatment for the patients with advanced prostate cancer. Androgen deprivation therapy initially suppresses the growth of prostate cancer. However, most patients eventually progress to castration-resistant prostate cancer. Novel drugs, including enzalutamide and abiraterone acetate, are recently able to be used for the patients with castration-resistant prostate cancer. Even so, the therapeutic options for castration-resistant prostate cancer are not enough. Interestingly, androgen receptor degradation enhancer ASC-J9 is reported to degrade the androgen receptor, resulting in the suppression of the growth in castration-resistant prostate cancer cells. In this chapter, ASC-J9 for prostate cancer is reviewed.

Original languageEnglish
Pages (from-to)2126-2129
Number of pages4
JournalNippon rinsho. Japanese journal of clinical medicine
Issue number12
Publication statusPublished - 2014 Dec 1


Dive into the research topics of '[ASC-J9 for castration-resistant prostate cancer]'. Together they form a unique fingerprint.

Cite this